Literature DB >> 16713540

Pancreatic cancer in sweden 1980-2000: a population-based study of hospitalized patients concerning time trends in curative surgery and other interventional therapies.

Stefan Linder1, Lennart Boström, Bo Nilsson.   

Abstract

Progress has been made during the last few decades in the treatment of patients with pancreatic cancer. In this population-based study, the time trends in curative surgery and the choice of palliative invasive therapies in Sweden over two decades are analyzed. Patients treated for pancreatic carcinoma in Sweden during 1980-2000 were identified in the Swedish Hospital Discharge Register and the Cancer Register. These data were matched with those in the Register of Causes of Death in Sweden. Data were identified and analyzed for 16,758 patients for three periods: 1980-1986 (n = 5775), 1987-1993 (n = 6096), and 1994-2000 (n = 4887). The rate of pancreatic resection increased 7.2%, 10.9%, and 15.1% (P < 0.0001) during the three respective periods. Palliative interventions decreased from 46.8% in the first period to 41.7% in the last period. On comparing the first and the last periods, biliary bypass operations were found to decrease (from 45.9% to 18.1%), as well as gastric bypass procedures (from 33.8% to 22.8%; P < 0.0001). Interventions by percutaneous transhepatic cholangiography (PTC) remained constant (10%-11%). Endoscopic therapy increased from 10.8% to 49.0%, as did the number of procedures per patient, from 1.3 to 1.7 (P < 0.0001) in the first and last periods, respectively. In 1980, the mean hospital stay was 40 days after resection and 30 days after palliative intervention. In 2000, the corresponding numbers were 26 days and 18 days (P < 0.001), respectively. During the past two decades, the rate of pancreatic resections in Sweden increased significantly. There was also a dramatic drop in palliative open surgery and a simultaneous increase in endoscopic interventions. Hospital stays decreased by more than a third.

Entities:  

Mesh:

Year:  2006        PMID: 16713540     DOI: 10.1016/j.gassur.2005.10.005

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  38 in total

Review 1.  Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?

Authors:  P Bachellier; H Nakano; P D Oussoultzoglou; J C Weber; K Boudjema; P D Wolf; D Jaeck
Journal:  Am J Surg       Date:  2001-08       Impact factor: 2.565

2.  Incidence, risk factors, and treatment of pancreatic leakage after pancreaticoduodenectomy: drainage versus resection of the pancreatic remnant.

Authors:  M I van Berge Henegouwen; L T De Wit; T M Van Gulik; H Obertop; D J Gouma
Journal:  J Am Coll Surg       Date:  1997-07       Impact factor: 6.113

Review 3.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

Review 4.  Pancreatic adenocarcinoma: an update.

Authors:  H P Tan; J Smith; C A Garberoglio
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

5.  Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization.

Authors:  J H Balcom; D W Rattner; A L Warshaw; Y Chang; C Fernandez-del Castillo
Journal:  Arch Surg       Date:  2001-04

6.  A continuing role for surgical bypass in the palliative treatment of pancreatic carcinoma.

Authors:  A M Isla; T Worthington; A K Kakkar; R C Williamson
Journal:  Dig Surg       Date:  2000       Impact factor: 2.588

7.  Cost and utilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy.

Authors:  G A Porter; P W Pisters; C Mansyur; A Bisanz; K Reyna; P Stanford; J E Lee; D B Evans
Journal:  Ann Surg Oncol       Date:  2000-08       Impact factor: 5.344

8.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

9.  Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy.

Authors:  Markus W Büchler; Markus Wagner; Bruno M Schmied; Waldemar Uhl; Helmut Friess; Kaspar Z'graggen
Journal:  Arch Surg       Date:  2003-12

10.  Secondary tumors of the pancreas: an analysis of a surgical and autopsy database and review of the literature.

Authors:  N Volkan Adsay; Aleodor Andea; Olca Basturk; Nihal Kilinc; Hind Nassar; Jeanette D Cheng
Journal:  Virchows Arch       Date:  2004-04-01       Impact factor: 4.064

View more
  5 in total

Review 1.  Palliative therapy in pancreatic cancer-interventional treatment with stents.

Authors:  Alexander Waldthaler; Wiktor Rutkowski; Roberto Valente; Urban Arnelo; J-Matthias Löhr
Journal:  Transl Gastroenterol Hepatol       Date:  2019-01-31

Review 2.  Radioimmunotherapy--a potential novel tool for pancreatic cancer therapy?

Authors:  Marie Sahlin; Monika Posaric Bauden; Roland Andersson; Daniel Ansari
Journal:  Tumour Biol       Date:  2015-04-30

Review 3.  A meta-analysis of randomized trials: immediate stent placement vs. surgical bypass in the palliative management of malignant biliary obstruction.

Authors:  Evan S Glazer; Mark C Hornbrook; Robert S Krouse
Journal:  J Pain Symptom Manage       Date:  2013-07-03       Impact factor: 3.612

4.  Surgical palliation for pancreatic malignancy: practice patterns and predictors of morbidity and mortality.

Authors:  Edmund K Bartlett; Heather Wachtel; Douglas L Fraker; Charles M Vollmer; Jeffrey A Drebin; Rachel R Kelz; Giorgos C Karakousis; Robert E Roses
Journal:  J Gastrointest Surg       Date:  2014-03-27       Impact factor: 3.452

5.  Pancreatic cancer survival in central and northern Denmark from 1998 through 2009: a population-based cohort study.

Authors:  Deirdre P Cronin-Fenton; Rune Erichsen; Frank V Mortensen; Sarunas Dikinis; Mette Nørgaard; Jacob Jacobsen
Journal:  Clin Epidemiol       Date:  2011-07-20       Impact factor: 4.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.